Advancements in pharmacological treatment of hypothalamic obesity
Hypothalamic obesity(HO)is obesity that occurs as a result of structural or functional damage to the hypothalamus.Its clinical features include hyperphagia,elevated energy intake,reduced en-ergy expenditure,hyperinsulinemia,etc.The intricate nature of the systems controlled by the hypothalamus in maintaining energy balance makes HO a persistent therapeutic obstacle.Currently,lifestyle interventions for HO are limited,and there are no specific pharmacological treatments.However,certain drugs have shown efficacy in the treatment of HO,including metformin combined with diazoxide,somatostatin,oxyto-cin,setmelanotide and glucagon-like peptide-1 receptor agonists(GLP-1RA),and Tesomet etc.These pharmaceutical drugs introduce novel therapeutic approaches for HO,providing the possibility to reduce symptoms and improve overall quality of life.
NETL
NSTL
万方数据
